Provided by Tiger Trade Technology Pte. Ltd.

NanoViricides

1.27
-0.0600-4.51%
Post-market: 1.290.0200+1.57%17:40 EDT
Volume:250.46K
Turnover:321.71K
Market Cap:32.38M
PE:-2.92
High:1.31
Open:1.31
Low:1.26
Close:1.33
52wk High:2.23
52wk Low:0.8500
Shares:25.50M
Float Shares:24.90M
Volume Ratio:0.90
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4355
EPS(LYR):-0.6263
ROE:-89.97%
ROA:-50.46%
PB:3.54
PE(LYR):-2.03

Loading ...

NanoViricides registers to sell 2.52M shares of common stock for holders

TIPRANKS
·
Aug 22

NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’

TIPRANKS
·
Aug 18

NanoViricides Wins DRC Acorep Clearance for Phase II NV-387 Ebola Treatment Trial

Reuters
·
Aug 18

NanoViricides, Inc: Received Regulatory Approval for a Phase Ii Clinical Trial of Nv-387 Oral Gummies as a Treatment for Ebola in DR Congo

THOMSON REUTERS
·
Aug 10

NanoViricides Wins DRC Approval for Phase II Trial of NV-387 Oral Gummies for Ebola Treatment

Reuters
·
Aug 10

NanoViricides Announces $3.8 Million Registered Direct Offering

TIPRANKS
·
Jul 30

NanoViricides Issues Warrants Exercisable at Us$1.75 in Us$3.8 Million Registered Direct Offering

Reuters
·
Jul 30

NanoViricides Raises Financing for Trial of Ebola Treatment, Awaits Regulatory Approval in Congo

MT Newswires Live
·
Jul 28

NanoViricides awaits regulatory approval to being Phase II trial of NV-387

TIPRANKS
·
Jul 28

NanoViricides Shares Fall Pre-Bell After $3.8 Million Direct Stock Sale Pricing

MT Newswires Live
·
Jul 24

NanoViricides prices $3.8M registered direct offering

TIPRANKS
·
Jul 24

Nanoviricides Prices Offering with 2,516,339 Warrants at US$ 1.75 Exercise Price

Reuters
·
Jul 24

NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial

TIPRANKS
·
Jul 22

Nanoviricides Seeks DR Congo Regulator Clearance for Phase II Ebola Trial of Nv-387 Oral Gummies

Reuters
·
Jul 22

Nanoviricides, Inc - Applied to Acorep for Approval to Begin Phase Ii Clinical Trial of Nv-387 Oral Gummies as Treatment for Bundibugyo Ebolavirus

THOMSON REUTERS
·
Jul 22

Nanoviricides, Inc: Sufficient Quantity of Nv-387 Oral Gummies Drug Product for Starting Clinical Trial Against Ebola is Already Available in Drc

THOMSON REUTERS
·
Jul 22

NanoViricides Establishes ATM Equity Sales Agreement

TIPRANKS
·
Jul 18

Nanoviricides Wins DRC Ethics Approval for Phase II Trial of Nv-387 Oral Gummies for Ebola

Reuters
·
Jul 13

Nanoviricides Rated Outperform at Noble Capital, Target Price $6

Reuters
·
Jul 08

NanoViricides initiated with an Outperform at Noble Capital

TIPRANKS
·
Jul 06